-
公开(公告)号:US08765148B2
公开(公告)日:2014-07-01
申请号:US13578686
申请日:2011-02-21
申请人: Benjamin Wizel , Karin Riedl , Karen Lingnau , Ursula Schlosser , Jürgen Wruss , Robert Schlegl , Michael Weber , Christoph Reinisch , Ljubomir Paucz , Christoph Klade , Jee Loon Look , Christian Ruiz , Robert Seid
发明人: Benjamin Wizel , Karin Riedl , Karen Lingnau , Ursula Schlosser , Jürgen Wruss , Robert Schlegl , Michael Weber , Christoph Reinisch , Ljubomir Paucz , Christoph Klade , Jee Loon Look , Christian Ruiz , Robert Seid
CPC分类号: A61K39/39 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/51 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K39/092 , A61K39/118 , A61K39/12 , A61K39/145 , A61K39/40 , A61K39/42 , A61K48/00 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/70 , C12N7/00 , C12N2760/16134 , C12N2760/16171 , C12N2760/16234 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396 , Y02A50/401 , Y02A50/412 , Y02A50/47
摘要: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.
摘要翻译: 本发明公开了液体形式的药物组合物,其包含具有氨基酸序列KLKL5KLK的肽和具有核酸序列(dIdC)13的寡脱氧核苷酸的肽,并且其中肽和寡脱氧核苷酸作为无菌可过滤纳米粒子存在于组合物中,由此形成 悬浮液,其特征在于固体颗粒的平均粒径小于1μm。
-
公开(公告)号:US20120308618A1
公开(公告)日:2012-12-06
申请号:US13578686
申请日:2011-02-21
申请人: Benjamin Wizel , Karin Riedl , Karen Lingnau , Ursula Schlosser , Jürgen Wruss , Robert Schlegl , Michael Weber , Christoph Reinisch , Ljubomir Paucz , Christoph Klade , Jee Loon Look , Christian Ruiz , Robert Seid
发明人: Benjamin Wizel , Karin Riedl , Karen Lingnau , Ursula Schlosser , Jürgen Wruss , Robert Schlegl , Michael Weber , Christoph Reinisch , Ljubomir Paucz , Christoph Klade , Jee Loon Look , Christian Ruiz , Robert Seid
IPC分类号: A61K39/39 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P33/00 , A61P33/02 , A61P31/04 , A61P31/10 , A61K9/14 , A61P31/22
CPC分类号: A61K39/39 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/51 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K39/092 , A61K39/118 , A61K39/12 , A61K39/145 , A61K39/40 , A61K39/42 , A61K48/00 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/70 , C12N7/00 , C12N2760/16134 , C12N2760/16171 , C12N2760/16234 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/394 , Y02A50/396 , Y02A50/401 , Y02A50/412 , Y02A50/47
摘要: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.
摘要翻译: 本发明公开了液体形式的药物组合物,其包含具有氨基酸序列KLKL5KLK的肽和具有核酸序列(dIdC)13的寡脱氧核苷酸的肽,并且其中肽和寡脱氧核苷酸作为无菌可过滤纳米粒子存在于组合物中,由此形成 悬浮液,其特征在于固体颗粒的平均粒径小于1μm。
-